Siemens Healthineers Navigates Alzheimer's Push Amid Operational Headwinds

Siemens Healthineers advances Alzheimer's blood tests but faces market headwinds, a Chinese slowdown, and U.S. tariffs as it moves toward a spin-off from Siemens AG.

Siemens Healthineers finds itself at a strategic crossroads. While the company is advancing its ambitions in the lucrative Alzheimer's diagnostics field and progressing toward independence from its parent, operational challenges and external pressures are weighing on its financial performance and share price, which recently touched a yearly low.

Strategic Moves and a Competitive Landscape

A key development came on March 18, when the firm announced the availability of two new research assays. Designed to run on its widely deployed Atellica analyzer platform, the Atellica IM pTau217 and Atellica IM BDTau tests measure Alzheimer's biomarkers from simple blood samples. This method offers a far less invasive alternative to the traditional lumbar puncture.

The potential market is substantial, with the Alzheimer's diagnostics sector projected to expand from approximately $9.2 billion in 2025 to over $21 billion by 2033. However, Siemens Healthineers faces stiff competition and regulatory hurdles. Its new assays are currently approved for research use only; clinical application requires further validation studies and regulatory approvals. Competitors have moved faster: Fujirebio Diagnostics secured the first FDA 510(k) clearance for a blood-based pTau217 test in May 2025, with Roche following by gaining approval for its Elecsys pTau181 assay. In response, Siemens Healthineers is leveraging its large installed base of analyzers and research collaborations, including the PREDICTOM and ACCESS-AD consortia and the Banner Sun Health Research Institute.

Operational Pressures and Financial Spin-Off Plans

This diagnostic push coincides with a difficult period for the division. In the first quarter of 2026, the Diagnostics segment contracted by 3%, primarily due to ongoing challenges in the Chinese market. While overall group revenue increased by 3.8%, adjusted earnings per share fell to €0.49. Growth was driven by the Imaging and Advanced Therapies units, not Diagnostics.

Further pressure stems from U.S. tariffs, which the company anticipates will have a negative impact of up to €500 million for fiscal 2026. The equity market has reflected this mixed picture, with the stock recently trading at a 52-week low of €36.37—about 19% below its 200-day moving average.

Amid these challenges, the path to financial independence from Siemens AG is progressing. A significant step was the assignment of an A3 credit rating with a stable outlook by Moody's. Siemens AG intends to deconsolidate its 67% stake and distribute 30% of Siemens Healthineers shares directly to its own shareholders via a spin-off. Specific details on the structure and timeline are expected early in the second quarter of 2026, potentially providing the next significant catalyst for the share price ahead of the Q2 results scheduled for May 7.